Henan Taloph Pharmaceutical Stock Co Ltd (600222) - Net Assets

Latest as of September 2025: CN¥1.65 Billion CNY ≈ $241.37 Million USD

Based on the latest financial reports, Henan Taloph Pharmaceutical Stock Co Ltd (600222) has net assets worth CN¥1.65 Billion CNY (≈ $241.37 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.74 Billion ≈ $547.03 Million USD) and total liabilities (CN¥2.09 Billion ≈ $305.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Henan Taloph Pharmaceutical Stock Co Ltd (600222) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥1.65 Billion
% of Total Assets	44.12%
Annual Growth Rate	11.11%
5-Year Change	6.25%
10-Year Change	8.46%
Growth Volatility	31.9

Henan Taloph Pharmaceutical Stock Co Ltd - Net Assets Trend (1996–2024)

This chart illustrates how Henan Taloph Pharmaceutical Stock Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 600222 current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Henan Taloph Pharmaceutical Stock Co Ltd (1996–2024)

The table below shows the annual net assets of Henan Taloph Pharmaceutical Stock Co Ltd from 1996 to 2024. For live valuation and market cap data, see Henan Taloph Pharmaceutical Stock Co Ltd stock valuation.

Year	Net Assets	Change
2024-12-31	CN¥1.63 Billion ≈ $237.97 Million	+0.18%
2023-12-31	CN¥1.62 Billion ≈ $237.55 Million	+0.58%
2022-12-31	CN¥1.61 Billion ≈ $236.19 Million	-9.20%
2021-12-31	CN¥1.78 Billion ≈ $260.12 Million	+16.14%
2020-12-31	CN¥1.53 Billion ≈ $223.97 Million	+16.68%
2019-12-31	CN¥1.31 Billion ≈ $191.96 Million	-5.71%
2018-12-31	CN¥1.39 Billion ≈ $203.58 Million	-7.76%
2017-12-31	CN¥1.51 Billion ≈ $220.70 Million	+0.55%
2016-12-31	CN¥1.50 Billion ≈ $219.49 Million	+0.04%
2015-12-31	CN¥1.50 Billion ≈ $219.41 Million	+26.41%
2014-12-31	CN¥1.19 Billion ≈ $173.57 Million	+8.58%
2013-12-31	CN¥1.09 Billion ≈ $159.85 Million	+66.40%
2012-12-31	CN¥656.50 Million ≈ $96.07 Million	+4.39%
2011-12-31	CN¥628.89 Million ≈ $92.03 Million	+3.21%
2010-12-31	CN¥609.32 Million ≈ $89.16 Million	+3.97%
2009-12-31	CN¥586.04 Million ≈ $85.76 Million	+5.60%
2008-12-31	CN¥554.97 Million ≈ $81.21 Million	+6.40%
2007-12-31	CN¥521.57 Million ≈ $76.32 Million	+7.09%
2006-12-31	CN¥487.05 Million ≈ $71.27 Million	+3.20%
2005-12-31	CN¥471.96 Million ≈ $69.06 Million	+3.57%
2004-12-31	CN¥455.68 Million ≈ $66.68 Million	+3.42%
2003-12-31	CN¥440.61 Million ≈ $64.48 Million	+2.88%
2002-12-31	CN¥428.30 Million ≈ $62.67 Million	+2.75%
2001-12-31	CN¥416.84 Million ≈ $61.00 Million	+1.57%
2000-12-31	CN¥410.41 Million ≈ $60.06 Million	+2.20%
1999-12-31	CN¥401.57 Million ≈ $58.76 Million	+159.34%
1998-12-31	CN¥154.84 Million ≈ $22.66 Million	+30.26%
1997-12-31	CN¥118.87 Million ≈ $17.39 Million	+39.67%
1996-12-31	CN¥85.11 Million ≈ $12.45 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Henan Taloph Pharmaceutical Stock Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 25845400000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥258.45 Million	16.41%
Common Stock	CN¥573.89 Million	36.44%
Other Comprehensive Income	CN¥173.87 Million	11.04%
Other Components	CN¥568.52 Million	36.10%
Total Equity	CN¥1.57 Billion	100.00%

Henan Taloph Pharmaceutical Stock Co Ltd Competitors by Market Cap

The table below lists competitors of Henan Taloph Pharmaceutical Stock Co Ltd ranked by their market capitalization.

Company	Market Cap
Zoje Resources Investment Co Ltd SHE:002021	$570.29 Million
Taekwang Ind KO:003240	$570.36 Million
Southern Cable Group Bhd KLSE:0225	$570.47 Million
Sijin Intelligent Forming Machinery SHE:003025	$570.50 Million
Nanfang Black Sesame Group Co Ltd SHE:000716	$570.04 Million
Atlanta Braves Holdings, Inc. Series A Common Stock NASDAQ:BATRA	$569.98 Million
Bouvet OL:BOUV	$569.94 Million
Ibotta, Inc. NYSE:IBTA	$569.94 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Henan Taloph Pharmaceutical Stock Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,578,494,000 to 1,574,729,000, a change of -3,765,000 (-0.2%).
Net income of 50,525,000 contributed positively to equity growth.
Dividend payments of 69,068,000 reduced retained earnings.
Share repurchases of 21,283,541 reduced equity.
Other comprehensive income decreased equity by 10,830,167.
Other factors increased equity by 46,891,708.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥50.52 Million	+3.21%
Dividends Paid	CN¥69.07 Million	-4.39%
Share Repurchases	CN¥21.28 Million	-1.35%
Other Comprehensive Income	CN¥-10.83 Million	-0.69%
Other Changes	CN¥46.89 Million	+2.98%
Total Change	CN¥-	-0.24%

Book Value vs Market Value Analysis

This analysis compares Henan Taloph Pharmaceutical Stock Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.40x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 32.88x to 2.40x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1996-12-31	CN¥0.21	CN¥6.79	x
1997-12-31	CN¥0.29	CN¥6.79	x
1998-12-31	CN¥0.35	CN¥6.79	x
1999-12-31	CN¥0.97	CN¥6.79	x
2000-12-31	CN¥1.00	CN¥6.79	x
2001-12-31	CN¥1.01	CN¥6.79	x
2002-12-31	CN¥1.04	CN¥6.79	x
2003-12-31	CN¥1.07	CN¥6.79	x
2004-12-31	CN¥1.11	CN¥6.79	x
2005-12-31	CN¥1.15	CN¥6.79	x
2006-12-31	CN¥1.18	CN¥6.79	x
2007-12-31	CN¥1.26	CN¥6.79	x
2008-12-31	CN¥1.31	CN¥6.79	x
2009-12-31	CN¥1.39	CN¥6.79	x
2010-12-31	CN¥1.44	CN¥6.79	x
2011-12-31	CN¥1.47	CN¥6.79	x
2012-12-31	CN¥1.52	CN¥6.79	x
2013-12-31	CN¥2.34	CN¥6.79	x
2014-12-31	CN¥2.14	CN¥6.79	x
2015-12-31	CN¥2.66	CN¥6.79	x
2016-12-31	CN¥2.59	CN¥6.79	x
2017-12-31	CN¥2.59	CN¥6.79	x
2018-12-31	CN¥2.42	CN¥6.79	x
2019-12-31	CN¥2.47	CN¥6.79	x
2020-12-31	CN¥2.66	CN¥6.79	x
2021-12-31	CN¥2.96	CN¥6.79	x
2022-12-31	CN¥2.77	CN¥6.79	x
2023-12-31	CN¥2.80	CN¥6.79	x
2024-12-31	CN¥2.83	CN¥6.79	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Henan Taloph Pharmaceutical Stock Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.21%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 2.60%
• Asset Turnover: 0.56x
• Equity Multiplier: 2.22x
Recent ROE (3.21%) is below the historical average (4.90%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1996	17.20%	14.90%	0.44x	2.65x	CN¥6.13 Million
1997	31.47%	24.02%	0.60x	2.18x	CN¥25.52 Million
1998	22.21%	23.54%	0.43x	2.21x	CN¥17.70 Million
1999	9.57%	22.94%	0.30x	1.38x	CN¥-1.72 Million
2000	9.81%	28.77%	0.24x	1.40x	CN¥-791.70K
2001	6.98%	21.37%	0.22x	1.50x	CN¥-12.57 Million
2002	2.55%	6.00%	0.26x	1.62x	CN¥-31.90 Million
2003	3.35%	8.67%	0.24x	1.61x	CN¥-29.33 Million
2004	3.56%	7.96%	0.28x	1.62x	CN¥-29.39 Million
2005	3.60%	6.78%	0.33x	1.59x	CN¥-30.25 Million
2006	2.75%	3.67%	0.45x	1.66x	CN¥-35.25 Million
2007	3.99%	5.58%	0.44x	1.63x	CN¥-31.17 Million
2008	4.28%	3.78%	0.65x	1.73x	CN¥-31.01 Million
2009	5.27%	3.71%	0.74x	1.91x	CN¥-27.05 Million
2010	4.10%	2.66%	0.73x	2.11x	CN¥-34.97 Million
2011	2.11%	1.30%	0.67x	2.41x	CN¥-47.77 Million
2012	3.23%	1.85%	0.69x	2.51x	CN¥-42.34 Million
2013	3.45%	2.76%	0.67x	1.87x	CN¥-68.42 Million
2014	3.01%	2.55%	0.55x	2.15x	CN¥-74.41 Million
2015	0.38%	0.55%	0.39x	1.78x	CN¥-142.52 Million
2016	0.27%	0.42%	0.36x	1.79x	CN¥-144.46 Million
2017	0.34%	0.44%	0.42x	1.88x	CN¥-143.85 Million
2018	-8.30%	-9.65%	0.42x	2.04x	CN¥-254.18 Million
2019	3.23%	3.39%	0.48x	1.99x	CN¥-93.09 Million
2020	2.01%	2.06%	0.42x	2.33x	CN¥-116.10 Million
2021	0.36%	0.37%	0.42x	2.28x	CN¥-160.06 Million
2022	-4.60%	-3.68%	0.54x	2.29x	CN¥-229.25 Million
2023	2.76%	2.10%	0.58x	2.27x	CN¥-114.29 Million
2024	3.21%	2.60%	0.56x	2.22x	CN¥-106.95 Million

Industry Comparison

This section compares Henan Taloph Pharmaceutical Stock Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,691,234,838
Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Henan Taloph Pharmaceutical Stock Co Ltd (600222)	CN¥1.65 Billion	17.20%	1.27x	$570.21 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$903.62 Million	4.28%	2.45x	$1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.22 Billion	5.35%	1.27x	$441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$5.01 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.80 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$3.04 Billion
Yunnan Baiyao Group Co Ltd (000538)	$9.03 Billion	25.71%	0.43x	$13.75 Billion
Hainan Haiyao Co Ltd (000566)	$275.57 Million	17.28%	1.12x	$947.33 Million
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.29 Billion	2.31%	2.07x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$18.87 Billion	8.83%	0.08x	$3.32 Billion

About Henan Taloph Pharmaceutical Stock Co Ltd

SHG:600222 China Drug Manufacturers - Specialty & Generic

Market Cap

$570.21 Million

CN¥3.90 Billion CNY

Market Cap Rank

#11884 Global

#3649 in China

Share Price

CN¥6.79

Change (1 day)

-0.15%

52-Week Range

CN¥5.17 - CN¥8.58

All Time High

CN¥10.35